RARE News and Press, Ultragenyx Pharmaceutical Inc. From 08/28/23

VANCOUVER, British Columbia, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Tactical Resources Corp. (CSE: RARE) (OTC: USREF) (“Tactical Resources” or the “Company”), a mineral exploration and development company focused on the rare earth elements that drive the critical technologi...

VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Tactical Resources Corp. (CSE: RARE) (OTC: USREF) (“Tactical Resources” or the “Company”), a mineral exploration and development company focused on the rare earth elements that drive the critical technologi...

2023-08-03 20:31:10 ET Ultragenyx Pharmaceutical, Inc. (RARE) Q2 2023 Earnings Conference Call August 03, 2023, 17:00 ET Company Participants Joshua Higa - Director, IR & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Eric Cromb...

2023-08-03 16:52:06 ET Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.25 misses by $0.15 . Revenue of $108.3M (+21.2% Y/Y) beats by $3.31M . For the full year 2023, the company expects: Total revenue in the range of $425 mi...

Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance betwe...

NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3 Cyprus 2 + study following completion of dosing and safety review in the first cohor...

NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...

2023-07-12 08:27:11 ET Biopharmaceutical company Ultragenyx Pharmaceutical ( NASDAQ: RARE ) said on Wednesday that it has appointed Howard Horn executive vice president and CFO, effective Oct. 16. Horn has been serving as the CFO of Vir Biotechnology. Source: P...

NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice pre...

Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical In...